News
NTLA
16.03
+3.42%
0.53
Short interest heatmap: Here are the most heavily bet-against stocks
Seeking Alpha · 1d ago
As AbbVie eyes Apogee, these biotech stocks earn the highest Quant ratings
Seeking Alpha · 3d ago
Weekly Report: what happened at NTLA last week (0615-0619)?
Weekly Report · 4d ago
Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera
NASDAQ · 06/19 09:09
Intellia Therapeutics rises 12.9%
TipRanks · 06/17 16:06
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday
Benzinga · 06/17 14:11
Intellia Therapeutics rises 10.7%
TipRanks · 06/17 14:07
Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA)
TipRanks · 06/16 09:32
Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watch
NASDAQ · 06/16 02:31
Intellia Therapeutics Shares Climb Following Positive Phase 3 Results
Dow Jones · 06/15 19:47
Midday Fly By: Fox to acquire Roku, Salesforce to buy Fin
TipRanks · 06/15 16:22
Sell Rating Maintained on Clinical and Commercial Uncertainty; $9 Price Target Reaffirmed
TipRanks · 06/15 15:15
Intellia Therapeutics Price Target Maintained With a $30.00/Share by Citizens
Dow Jones · 06/15 14:19
Wedbush Remains a Hold on Intellia Therapeutics (NTLA)
TipRanks · 06/15 14:16
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target
Benzinga · 06/15 14:09
Intellia Therapeutics Price Target Maintained With a $12.00/Share by Wedbush
Dow Jones · 06/15 13:57
Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price Target
Benzinga · 06/15 13:47
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
Benzinga · 06/15 13:39
Intellia Highlights Strong Phase 3 Lonvo-z HAE Results
TipRanks · 06/15 13:23
Intellia says Phase 3 HAELO trial shows 87% attack reduction with lonvo-z in hereditary angioedema
PUBT · 06/15 12:53
More
Webull provides a variety of real-time NTLA stock news. You can receive the latest news about Intellia Therape through multiple platforms. This information may help you make smarter investment decisions.
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.